Chemotherapy during pregnancy

Current Opinion in Oncology

Volumn 24, Issue 5, 2012, Pages 580-586

  Amant, Frédéric ^a   Han, Sileny N ^a   Gziri, Mina M ^a   Dekrem, Jana ^a   Van Calsteren, Kristel ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

cancer; chemotherapy; neonatal; pregnancy; transplacental

Indexed keywords

4 HYDROPEROXYIFOSFAMIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BETAMETHASONE; CARBOPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARDIOTOCOGRAPHY; CARDIOTOXICITY; CESAREAN SECTION; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHORIOAMNIONITIS; DELIVERY; DRUG PENETRATION; ECHOGRAPHY; FETUS DEVELOPMENT; FETUS HEART; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; MOLECULAR WEIGHT; NEOPLASM; NERVE CELL DIFFERENTIATION; NONHUMAN; ORGANOGENESIS; PLACENTA; PREGNANCY; PREMATURE LABOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 84865446247     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328354e754     Document Type: Review

References (49)

1. Amant F, Van Calsteren K, Halaska M, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18months or older: an observational study. Lancet Oncol 2012; 13:256-264.
2. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 2010; 28:683-689.
3. Saigal S, Doyle L. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008; 371:261-269.
4. Avilé s A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001; 2:173-177. (Pubitemid 34092723)
5. Hahn K, Johnson P, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107:1219-1226. (Pubitemid 44452769)
6. Aviles A, Neri N, Nambo M. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol 2006; 17:286-288. (Pubitemid 43160119)
7. Roboz J, Gleicher N, Wu K, et al. Does doxorubicin cross the placenta? Lancet 1979; 2:1382-1383. (Pubitemid 10199381)
8. Gedeon C, Behravan J, Koren G, Piquette-Miller M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 2006; 27:1096-1102. (Pubitemid 44400512)
9. Grohard P, Akbaraly J, Saux M, et al. Transplacental passage of doxorubicin. J Gynecol Obstet Biol Reprod 1989; 18:595-600.
10. Gaillard B, Leng J, Grellet J, et al. Transplacental passage of epirubicin. J Gynecol Obstet Biol Reprod 1995; 24:63-68.
11. Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol 2010; 119:594-600.
12. Van Calsteren K, Verbesselt R, Van Bree R, et al. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci 2011; 18:57-63.
13. Van Calsteren K, Verbesselt R, Devlieger R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin and trastuzumab in a baboon model. Int J Gynecol Cancer 2010; 20:1456-1464.
14. Krauer B, Krauer F, Hytten F. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980; 10:301-328.
15. Dawes M, Chowienczyk P. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol 2001; 15:819-826. (Pubitemid 34036629)
16. Van Calsteren K, Verbesselt R, Ottevanger P, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a Preclinical and Clinical Study. Acta Obstet Gynecol Scand 2010; 89:1338-1345.
17. Stensheim H, Møller B, van Dijk T, Fossa S. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registrybased cohort study. J Clin Oncol 2009; 27:45-51.
18. Cardonick E, Dougherty R, Grana G, et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 2010; 16:76-82.
19. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2007; 57:43-66.
20. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283-291. (Pubitemid 38541580)
21. Walton J, Prasad M. Obstetric and neonatal outcomes of cancer treated during pregnancy. Clin Obstet Gynecol 2011; 54:567-573.
22. Mennes M, Stiers P, Vandenbussche E, et al. Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr Blood Cancer 2005; 44:479-486. (Pubitemid 40614496)
23. Ring A, Smith I, Jones A, et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23:4192-4197. (Pubitemid 46211325)
24. Lohaugen G, Gramstad A, Evensen K, et al. Cognitive profile in young adults born preterm at very low birthweight. Dev Med Child Neurol 2010; 52:1133-1138.
25. Voigt B, Pietz J, Pauen S, et al. Cognitive development in very vs. moderately to late preterm and full-term children: can effortful control account for group differences in toddlerhood? Early Hum Dev 2012; 88:307-313.
26. van Baar A, Vermaas J, Knots E, et al. Functioning at school age of moderately preterm children born at 32 to 36 weeks' gestational age. Pediatrics 2009; 124:251-257.
27. van den Bergh B, Mennes M, Stevens V, et al. ADHD deficit as measured in adolescent boys with a continuous performance task is related to antenatal maternal anxiety. Pediatr Res 2006; 59:78-82.
28. Lipshultz S, Scully R, Lipsitz S, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11:950-961.
29. Sawyer D, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 2010; 53:105-113.
30. Chen B, Peng X, Pentassuglia L, et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007; 7:114-121. (Pubitemid 47339857)
31. Minotti G, Mancuso C, Frustaci A, et al. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. J Clin Invest 1996; 98:650-661. (Pubitemid 26349169)
32. De Keulenaer G, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 2010; 106:35-46.
33. von Hoff D, Layard M, Rozencweig M, Muggia F. Time relationship between last dose of daunorubicin and congestive heart failure. Cancer Treat Rep 1977; 61:1411-1413. (Pubitemid 8204120)
34. Franco V, Henkel J, Miller T, Lipshultz S. Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract 2011; 2011:134679.
35. Achtari C, Hohlfeld P. Cardiotoxic transplacental effect of idarubicin administered during the decond trimester of pregnancy. Am J Obstet Gynecol 2000; 183:511-512. (Pubitemid 30651112)
36. Baumgartner A, Oberhoffer R, Jacobs V, et al. Reversible foetal cerebral ventriculomegaly and cardiomyopathy under chemotherapy for maternal AML. Onkologie 2009; 32:40-43.
37. Reynoso E, Huerta F. Acute leukemia and pregnancy: fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994; 33:703-716.
38. Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004; 15:146-150. (Pubitemid 38139617)
39. Van Calsteren K, Ganame J, Lagae L, et al. In utero exposure of chemotherapy: effect on cardiac and neurological outcome. J Clin Oncol 2006; 24:e16-e17.
40. Blanford A, Murphy B. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977; 127:264-267. (Pubitemid 8040586)
41. Tamaru S, Kikuchi A, Takagi K, et al. Neurodevelopmental outcomes of very low birth weight and extremely low birth weight infants at 18 months of corrected age associated with prenatal risk factors. Early Hum Dev 2011; 87:55-59.
42. Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 2006; 106:237-246. (Pubitemid 43100430)
43. Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer 2010; 46:3158-3168.
44. Sorosky J, Sood A, Buekers T. The use of chemotherapeutic agents during pregnancy. Obstet Gynecol Clin North Am 1997; 24:591-599. (Pubitemid 27333106)
45. Dessolle L, Dalmon C, Roche B, Darai E. Placental metastases from maternal malignancies: review of the literature. J Gynecol Obstet Biol Reprod 2007; 36:344-353. (Pubitemid 46818768)
46. Daneman R, Zhou L, Kebede A, Barres B. Pericytes are required for bloodbrain barrier integrity during embryogenesis. Nature 2010; 468:562-566.
47. Saunders N, Ek C, Habgood M, Dziegielewska K. Barriers in the brain: a renaissance? Trends Neurosci 2008; 31:279-286.
48. Virgintino D, Errede M, Girolamo F, et al. Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development. J Neuropathol Exp Neurol 2008; 67:50-61.
49. Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet 2012; 379:570-579.